Responsive Dropdown with Links
Uniphar triquetra

IND Submission Support for Drug Development Programs

Author, Compile, and File IND Submissions with Confidence

Comprehensive IND Preparation: Strategic Planning to Execution

Preparing an IND requires more than document assembly. It takes coordinated planning, clear functional ownership, and experienced execution across the components that drive submission readiness. Uniphar supports biotech and pharma teams as they move toward first-in-human development.

Build a Stronger IND with the Right Strategy and Execution Support

Uniphar helps sponsors prepare for IND submission with practical support across planning, coordination, and development readiness. The focus is not just on filing, but on helping teams move forward with greater confidence and fewer avoidable delays.

Our IND Support Includes:

IND Work Is Cross-Functional by Definition

An IND does not move smoothly when functions operate in parallel without enough integration. Internal Uniphar planning explicitly maps IND work across scientific and strategy leads, regulatory and medical writing, clinical pharmacology, and program / delivery management.

What Sponsors Often Need Most

Typical IND Use Cases

Free Download

Free Download: FDA Meeting Mastery: A Guide to Go from Request to Regulatory Win

Reduce uncertainty and strengthen every FDA interaction.

Why Uniphar

Uniphar’s strength is experienced, senior-led execution across the functions that matter most to development programs. Internal positioning emphasizes continuous senior leadership engagement, embedded scientific expertise, and rapid activation through established systems and delivery infrastructure.

Uniphar Development Proven Scale and Delivery Experience

Organizations supported
0 +
Integrated programs advanced
0 +
Years development success
0 + Yrs
Asset value creation
$ 0 .0B+

Featured Case Study

An eleven-year development partnership advanced to a worldwide licensing agreement.

Uniphar (formerly RRD Biopharma Development) had an eleven-year development partnership with Nitto on multiple assets utilizing its novel siRNA technology to develop antifibrotic medicines targeting advanced hepatic fibrosis due to non-alcoholic steatohepatitis (NASH), and Idiopathic Pulmonary Fibrosis (IPF). Uniphar supported advancement of Nitto’s assets
through Phase 2 clinical trials.

The partnership enabled Nitto to enter into an exclusive worldwide licensing agreement with Bristol Myers Squibb — including a $100 million upfrontSquibb payment and subsequent development milestones and royalties.

DEVELOPMENT PARTNERSHIP
0 Yrs
CLINICAL TRIAL MILESTONE
Ph 0
UPFRONT LICENSING PAYMENT
$ 0 M

IND Submission Services FAQs

Yes, Uniphar provides support for CMC and clinical pharmacology components as part of IND submissions.

Uniphar can assist with individual sections or manage the entire IND submission, depending on your needs.

Yes, Uniphar offers post-Pre-IND meeting support to help you advance toward successful filing.

Complimentary 30-Minute Consultation with a Senior Program Leader (one who actually does the work)

Meet directly with a senior Uniphar leader to discuss your IND timing, cross-functional readiness, and the steps needed to reduce submission risk and move efficiently toward filing.